Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer

Medical Oncology

Volumn 21, Issue 2, 2004, Pages 167-177

  Khan, Tanweera S ^a   Sundin, Anders ^a   Juhlin, Claes ^a   Wilander, Erik ^a   Öberg, Kjell ^a   Eriksson, Barbro ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adrenocortical cancer; Combination chemotherapy; OPEC; Side effects; Survival; Therapeutic responses

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; STREPTOZOCIN; TENIPOSIDE; VINCRISTINE;

ADRENAL CANCER; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EVALUATION; FEMALE; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADRENAL CORTEX NEOPLASMS; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TENIPOSIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 4243074009     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:21:2:167     Document Type: Article

References (34)

1. Norton JA, Le HN. Adrenal tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: principles & practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2000, pp. 1770-1788.
2. Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg 1991; 126(4):457-461.
3. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112(6):963-970; discussion 970-971.
4. Grondal S, et al. Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 1990; 16(6):500-506.
5. Bargenstal DM, Hertz R, Lipsett MB, Moy RH. Chemotherapy of adrenocortical cancer with p, p′DDD. Ann Intern Med 1960; 53:672-682.
6. Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg 1982; 117(9):1142-1146.
7. Heilmann P, Wagner P,Nwroth PP, Ziegler R. Therapy of the adrenocortical carcinoma with Lysodren (o,p′-DDD). Therapeutic management by monitoring o,p′-DDD blood levels. Med Klin 2001; 96(7):371-377.
8. Icard P, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25(7):891-897.
9. Eriksson B, et al. Treatment of hormone-producing adrenocortical cancer with o,p′DDD and streptozocin. Cancer 1987; 59(8):1398-1403.
10. Khan TS, et al. Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000; 11(10):1281-1287.
11. Luton JP, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322(17):1195-1201.
12. Schteingart, D. Treating adrenal cancer. Endocrinologist 1992; 2:149-157.
13. Hesketh PJ, et al. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 1987; 71(2):222-224.
14. Williamson SK, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000; 88(5):1159-1165.
15. Berruti A, et al. Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases. Tumori 1992; 78(5):345-348.
16. Zidan J, Shpendler M, Robinson E. Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p′DDD. Clinical case reports. Am J Clin Oncol 1996; 19(3):229-231.
17. Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986; 58(10):2198-2202.
18. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 1998; 83(10):2194-2200.
19. Ahlman H, et al. Cytotoxic treatment of adrenocortical carcinoma. World J Surg 2001; 25(7):927-933.
20. Haq MM, Legha SS, Samaan NA, Bodey GP, Burgess MA. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 1980; 64(8-9):909-913.
21. Arico M, Bossi G, Livieri C, Raiteri E, Seven F. Partial response after intensive chemotherapy for adrenal cortical carcinoma in a child. Med Pediatr Oncol 1992; 20(3):246-248.
22. Crock PA, Clark AC. Combination chemotherapy for adrenal carcinoma: response in a 5 1/2- year-old male. Med Pediatr Oncol 1989; 17(1):62-65.
23. Grondai S, Eriksson B, Hagenas L, Werner S, Curstedt T. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol (Copenh) 1990; 122(5):656-663.
24. WHO handbook for reporting results of cancer treatment. Geneva: WHO Offset Publication; 1979.
25. Schulick RD, Brennan MF. Adrenocortical carcinoma. World J Urol 1999; 17(1):26-34.
26. Hutter AM Jr., Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o,p′DDD in 138 patients. Am J Med 1966; 41(4):581-592.
27. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973; 223(10):1109-1112.
28. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72(11):3145-3155.
29. Brennan MF. Adrenocortical carcinoma. CA Cancer J Clin 1987; 37(6):348-365.
30. Bukowski RM, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 1993; 11(1):161-165.
31. Abraham J, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002; 94(9):2333-2343.
32. Schlumberger M, et al. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991; 67(12):2997-3000.
33. Dogliotti L, et al. Cytotoxic chemotherapy for adrenocortical carcinoma. Minerva Endocrinol 1995; 20(1):105-109.
34. Tweddle DA, et al. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Med Pediatr Oncol 2001; 36(1):239-242.